Management of Hepatitis C Infection
Summary
- Pibrentasvir is an NS5A inhibitor
- Pibrentasvir is approved by the FDA and the EMA as part of the coformulation glecaprevir/pibrentasvir for first-line treatment of genotypes 1-6 chronic HCV infection[FDA Glecaprevir Pibrentasvir; EMA Glecaprevir Pibrentasvir]
- Some treatment-experienced patients are also eligible for treatment with this coformulation, depending on the type of agent previously used and HCV genotype
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Hepatitis C-Treatment